Industry versus academic: which trials actually pay

Newcomers to clinical research often assume the field is dominated by pharma. By trial count, the opposite is true: most registered trials are academic and institutional, not industry. But most of the well-paid careers are on the industry side. Understanding that split, and why it exists, is the difference between building a career where the money is and grinding where it is not.

The split

Registered studies by lead sponsor type, from the public registry:

• Academic, hospital, and other non-industry: about 425,000 total, with roughly 51,600 currently recruiting
• Industry: about 131,000 total, with roughly 10,300 currently recruiting
• Government and NIH combined: about 27,000 total

Read the recruiting numbers, because those are the live work. Of all recruiting trials, industry sponsors only about one in six. Academic and institutional sponsors run the clear majority. If you pictured clinical research as mostly pharma, the registry says you had it backwards on volume.

Why the paid jobs are in the smaller slice

Volume and pay point in opposite directions here. Academic and hospital trials are numerous but tend to be small, single-site, investigator-led, and thinly funded. They are run by coordinators, sub-investigators, and research staff on institutional salaries, often as one part of a clinical or academic job rather than a dedicated career. Vital work, but not where the money is.

The industry slice is smaller in count but concentrated in funded, multi-site programs that hire dedicated professionals: the CRAs, biostatisticians, programmers, data managers, and project managers this site is written for. The government filings on our salaries page, senior CRAs in the low $120,000s, principal programmers above $150,000, are all industry-side numbers. The academic side rarely pays like that, because the funding structure is completely different.

What this means for a career

If your goal is a well-compensated clinical research career, the registry is telling you to aim for the industry one in six, not the academic five in six. That usually means a CRO or a sponsor, not a site or a university, even though the sites and universities run more trials. It also explains a common career arc: people start on the academic or site side, where it is easier to break in, and move to industry, where it pays, once they have the experience. We covered that on-ramp separately; the sponsor-type split is the money reason it exists.

None of this diminishes academic research. It is where a lot of important science and a lot of careers live. But it is an honest map: the volume is academic, the pay is industry, and confusing the two is how people end up underpaid in a field they assume pays well.

What the registry cannot tell you

The registry sorts trials by sponsor type. It cannot tell you the actual pay gap between an academic coordinator and an industry CRA, or how much the jump from site to sponsor is really worth, because none of that is in the trial record. That gap is the whole question for someone deciding which side to build on, and it lives only in what workers report. The salary survey collects employer type alongside pay for exactly this comparison. Whichever side you are on, add your datapoint, and the map from volume to money gets real numbers.